Table 1 Summary of economic features of the studies
Feature | N | % |
|---|---|---|
Type of economic evaluation | ||
 CEA | 8 | 42 |
 CUA | 11 | 58 |
 CMA | 0 | 0 |
 CBA | 0 | 0 |
Study design | ||
 Randomised clinical trial (RCT) | 0 | 0 |
 Observational | 4 | 21 |
 Modelling | 15 | 79 |
Perspective evaluated | ||
 Government/public sector | 4 | 21 |
 Provider | 8 | 42 |
 Program provider | 2 | 11 |
 Not specified | 5 | 26 |
Time horizon | ||
 ≤ 1 year | 4 | 21 |
 1–10 years | 4 | 21 |
 Over 10 years/lifetime | 5 | 26 |
 Not specified | 6 | 32 |
Type of outcome | ||
 QALY/DALY | 11 | 58 |
 Infection averted | 12 | 63 |
 Infections cured | 3 | 16 |
Level of care and intervention type | ||
 Behavior change | 1 | 5 |
 Biomedical interventions | 4 | 21 |
 Structural interventions | 1 | 5 |
 Mixed | 13 | 68 |
Type of data used | ||
 Primary data | 2 | 11 |
 Secondary data | 15 | 79 |
 Mixed | 2 | 11 |
Type of sensitivity analysis | ||
 One-way/univariate | 12 | 63 |
 Multi-way/multivariate | 8 | 42 |
 Probabilistic analysis | 6 | 32 |
 Not performed/specified | 2 | 11 |